Spontaneous expression of the CIC::DUX4 fusion oncoprotein from a conditional allele potently drives sarcoma

Peter G Hendrickson1, Kristianne M Oristian1, MaKenna R Browne1,2

  • 1Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA.

Oncogene
|February 27, 2024
PubMed

Insights

Researchers developed new mouse models for CIC::DUX4 sarcoma (CDS), a rare cancer. These models spontaneously develop tumors, aiding the study of this aggressive disease and the search for effective therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • CIC::DUX4 sarcoma (CDS) is a rare, aggressive cancer driven by the CIC::DUX4 fusion.
  • Effective treatments are lacking due to limited patient samples and cell lines.

Purpose of the Study:

  • To generate and validate genetically engineered mouse models for CDS.
  • To overcome limitations in studying CDS due to sample scarcity.

Main Methods:

  • Generation of three conditional mouse models (Ch7CDS, Ai9CDS, TOPCDS).
  • Observation of spontaneous, Cre-independent tumor formation.
  • Characterization of tumors and generation of tumor-derived cell lines.
  • ChIP-seq to map CIC::DUX4 binding and H3K27ac profiles.

Main Results:

  • All three models developed spontaneous soft tissue tumors and disseminated disease.
  • Tumor formation was complete and Cre-independent.
  • Validated CIC::DUX4 as a neomorphic transcriptional activator.
  • Identified ETS family transcription factors as drivers of CDS regulatory circuitry.

Conclusions:

  • The developed mouse models are effective tools for studying CDS.
  • CIC::DUX4 acts as a potent transcriptional activator in CDS.
  • ETS factors play a crucial role in the core regulatory network of CDS.